secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0000950170-25-101971
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics enters 5-year manufacturing supply agreement with ACS Dobfar for ORLYNVAH
--------------------------------------------------------------------------------

- Agreement covers commercial manufacture and supply of ORLYNVAH bilayer tablets and sulopenem etzadroxil bulk drug substance.
- Initial term of 5 years with a 2-year automatic renewal; pricing based on per kg or per bottle.
- Iterum Ireland provides rolling forecasts, with portion binding as firm orders; ACS to use commercially reasonable efforts for above-forecast orders.
- Agreement includes customary IP protection, confidentiality, insurance, indemnification, and cGMP compliance obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025101971/0000950170-25-101971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025101971/itrm-20250729.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-101971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer